Peptide CDMO capacity is the binding constraint on the next wave of peptide therapeutics. Bachem, PolyPeptide, CordenPharma, and AmbioPharm together hold an estimated 55–60% of global peptide CDMO revenue, and their capacity decisions determine which GLP-1, macrocyclic, and conjugate programs can actually be supplied at commercial scale.
The ResearchAndMarkets April 30 forecast pegs the global peptide and oligonucleotide CDMO market at $2.7B in 2026, growing to $4.03B by 2030 (11.9% CAGR). The current build-out: Bachem expanding Bubendorf, scaling Vista to 1-metric-ton US capacity, upgrading St Helens, and constructing the new Sisslerfeld site in Switzerland; PolyPeptide doubling SPPS capacity at Malmö, starting large-scale SPPS at Braine-l'Alleud, Belgium in late 2024, and expanding its credit facility to EUR 200M in May 2026 to fund the strategic plan to double 2023 revenue by 2028; CordenPharma confirming a $500M Boulder expansion to 42,000+ L by 2028 plus a >€500M greenfield site near Basel for €900M+ total platform investment; AmbioPharm scaling US-based supply. The TIDES USA 2026 conference (May 11–14, Boston) headlines the CMC strategy conversation.
Stories here cover capacity expansions, contract wins, and the GLP-1 supply economy. See #bachem, #cordenpharma, and #manufacturing.
Global Peptide Synthesis Market Outlook Report 2026-2035 was published August 31, 2026 via ResearchAndMarkets, projecting global peptide synthesis market growth from $4.4 billion in 2026 to $7.0 billion by 2035 (5.2% CAGR). Growth drivers: growing peptide therapeutics pipeline, rising demand for peptide active pharmaceutical ingredients, continued investment in manufacturing infrastructure, and increased outsourcing to specialized peptide CDMOs. Named anchor programs: CordenPharma more than EUR 900 million capacity investment; PolyPeptide doubling capacity at its Malmö site (in the context of the pending Samsung Biologics acquisition); Cambrex expanding its Waltham, Massachusetts facility. Regulatory context: authorities worldwide have approved nearly 100 peptide-based therapies across cancer, diabetes, chronic pain, HIV, multiple sclerosis, and osteoporosis. Report caveats: the top-line 5.2% CAGR reflects a broad market definition; a narrower peptide CDMO subsegment (Bachem, PolyPeptide, CordenPharma, AmbioPharm) is growing at 20%+ CAGR per multiple industry data sources given the incretin surge.
Peptide CDMO announced investments have crossed $2.4 billion year-to-date in 2026, driven primarily by GLP-1 demand and a broadening pipeline of therapeutic peptides beyond the incretin class. Anchor programs: Samsung Biologics' CHF 1.46 billion / $1.8 billion all-cash tender offer for PolyPeptide Group AG (tender prospectus targeted for end-of-August publication, offer period September 15 to October 12); Bachem's more than CHF 500 million Sisslerfeld greenfield site collaboration in Switzerland (commercial production 2030) plus the recent Building K commercial GMP ramp; CordenPharma's confirmed $500 million Boulder expansion to 42,000+ liters by 2028 plus greater-than-€500 million greenfield near Basel; AmbioPharm's US-based supply scaling; and Lonza's SPPS capacity extensions. The global peptide CDMO market reached $4.59 billion in 2025 and is projected to reach $29.12 billion by 2035 (CAGR 20.3%) according to newly-published market research. The build-out is the binding upstream constraint on how much of the GLP-1, macrocyclic, and peptide-drug-conjugate pipeline reaches commercial scale.
Samsung Biologics' $1.8 billion (CHF 1.46 billion) all-cash tender offer for Swiss peptide CDMO PolyPeptide Group (SIX: PPGN) is scheduled to publish the formal offer prospectus by the end of August 2026, following the mandatory 10 trading-day cooling-off period under Swiss takeover law. Terms: CHF 44.31 per share (40% premium to the CHF 31.65 undisturbed price on April 10, 2026). The offer will run for a minimum of 20 trading days on SIX Swiss Exchange and is conditioned on at least 66⅔% of shares tendered on a fully diluted basis plus customary regulatory approvals. Deal close is targeted for end of 2026, after which Samsung intends to squeeze out remaining minorities and delist PolyPeptide. The transaction would give Samsung Biologics one of the top three peptide CDMO capacity positions globally, integrated with Samsung's existing multi-modality biologics network across the U.S., Europe, and India.
The broader peptide contract development and manufacturing organization (CDMO) consolidation wave continues across August 2026 with three concurrent developments. First, Samsung Biologics' pending $1.8 billion all-cash tender offer for PolyPeptide Group AG at CHF 44.31 per share (CHF 1.46 billion total equity value, 40% premium to undisturbed share price) advances toward closing: the formal tender offer prospectus is expected to be published by end of August 2026 following Draupnir Holding B.V. (55.65% stake) commitment to tender and PolyPeptide's Board of Directors unanimous recommendation, with closing expected toward end of 2026. Second, Gland Pharma and Neuland Laboratories announced August 11, 2026 a long-term sterile API manufacturing partnership in Visakhapatnam, India, extending India's growing role as a peptide API manufacturing hub. Third, Bachem, CordenPharma, and AmbioPharm continue capacity build-outs. Collective capacity positioning targets the multi-billion-dollar demand wave from semaglutide and tirzepatide commercial-scale API (roughly $17 billion combined active pharmaceutical ingredient market by 2028 per industry estimates) plus retatrutide, amycretin, VK2735, ribupatide, and next-generation combination peptide Phase 3 programs. The consolidation trajectory suggests peptide CDMO capacity concentration among a smaller number of large operators through the end of the decade, with the Samsung acquisition of PolyPeptide as the anchor transaction.
Samsung Biologics' all-cash tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share (CHF 1.46 billion / $1.8 billion, representing a 40% premium to the undisturbed share price of CHF 31.65) continues to progress. The formal tender offer prospectus is expected to be published by end of August 2026 and will remain open for a minimum of twenty trading days on the SIX Swiss Exchange following a ten trading-day cooling-off period under Swiss takeover law. PolyPeptide's largest individual shareholder Draupnir Holding B.V. (owning approximately 55.65% of shares outstanding) has committed to tender all of its shares into the offer. PolyPeptide's independent Board of Directors unanimously recommends that shareholders accept Samsung Biologics' offer. The transaction would substantially expand Samsung Biologics' peptide CDMO manufacturing footprint beyond its existing antibody and antibody-drug conjugate focus, positioning the combined entity to address the rapidly growing peptide therapeutics demand particularly in obesity and diabetes GLP-1 therapies (Novo Nordisk Wegovy and Ozempic, Eli Lilly Zepbound and Mounjaro), amylin analogs (cagrilintide), and next-generation combination peptide drugs. PolyPeptide operates commercial-scale peptide API manufacturing across the US, Europe, and India. Closing is expected towards the end of 2026 subject to a minimum acceptance threshold of 66⅔% and applicable regulatory approvals.
Bachem AG (SIX: BANB) announced May 25, 2026 that Chief Commercial Officer Torsten Wöhr decided to pursue a new opportunity outside the company. CEO Anne-Kathrin Stoller — who succeeded Thomas Meier as CEO on January 1, 2026 after 19 years at Bachem in increasingly senior roles (Head of Business Development & Sales Europe, Chief Marketing Officer, COO Americas) — assumed the CCO role in addition to her CEO responsibilities until a successor is appointed. Bachem is one of two major peptide CDMOs supplying the global GLP-1 API market alongside PolyPeptide; the company is in the middle of multi-site capacity expansion across Switzerland (Bubendorf Module I completion H1 2026) and the US (San Diego, King of Prussia). The CCO transition follows months of senior turnover and comes as GLP-1 manufacturing capacity has become the rate-limiting constraint for the entire commercial peptide industry.
The FDA announced an AI-Informed Inspection Pilot on May 15, 2026, applying machine-learning analysis to facility inspection prioritization and execution. The program is part of the FDA's Pharmaceutical Quality/Manufacturing Standards initiative and will affect peptide-manufacturing sites including 503A compounding pharmacies, 503B outsourcing facilities, and full-scale peptide CDMOs. AI inputs include historical inspection findings, FAERS adverse-event signals, supply-chain risk indicators, and recall history. The pilot lands during a sensitive compounding-pharmacy regulatory cycle ahead of the July 23-24 PCAC meeting on seven peptides for 503A bulks-list inclusion (BPC-157, KPV, TB-500, MOTs-C, Emideltide/DSIP, Semax, Epitalon) and against the April 30 503B bulks-list proposal closing comments June 29. Industry response is mixed: faster inspection cycles could ease compliance burden for well-run facilities but may concentrate enforcement on the gray-market segment.
TIDES USA 2026 wrapped at the Hynes Convention Center in Boston on Thursday May 14 after four days of peptide and oligonucleotide CDMO programming. The CMC strategy tracks featured Bachem, PolyPeptide, CordenPharma, AmbioPharm, and Gilead on GMP capacity, large-scale SPPS economics, and the supply-chain economics of oral macromolecule manufacturing. The closing-day Robert Langer keynote framed peptide-LNP delivery as the next major engineering frontier. The conference concluded with Catalent's Zydis fast-dispersion + oral macromolecule platform presentations and Novo Nordisk's CMC strategy panel on oral semaglutide and the next-generation amycretin program. The week's combined manufacturing footprint (TIDES + the PolyPeptide EUR 200M credit facility on May 9 + the May 6 Lilly Lebanon $4.5B investment) anchors the CDMO buildout heading toward the 2028 capacity targets.
PolyPeptide Group AG announced that it has expanded its existing credit facility to EUR 200 million in support of growth ambitions and progress toward doubling 2023 revenue by 2028. The Swedish-Belgian peptide CDMO is one of the four large dedicated peptide manufacturers — alongside Bachem, CordenPharma, and Sun Pharma's Hyderabad PolyPeptide platform — and has previously announced a EUR 100M expansion in Malmö plus large-scale SPPS production in Braine-l'Alleud, Belgium that started in late 2024. The credit move heads into TIDES USA 2026 (May 11–14, Boston), where capacity, GMP investment, and large-scale SPPS economics will dominate the panel agenda.
Two of the year's biggest peptide-related meetings open within 24 hours of each other next week. The European Congress on Obesity 2026 runs May 12–15 in Istanbul, with Novo Nordisk presenting 52 abstracts spanning Wegovy 7.2 mg full STEP UP data, CagriSema higher-dose Phase 3 plans, Wegovy pill efficacy and tolerability, and women's-obesity / perimenopause / migraine subgroups; the 21-expert global panel will also formally propose the 10-year prospective GLP-1 cancer-prevention trial. TIDES USA 2026 runs May 11–14 in Boston with six concurrent scientific tracks across oligonucleotides, peptides, and mRNA — featuring Bachem, PolyPeptide, CordenPharma, Gilead, and Novo Nordisk on the CMC strategy and GMP capacity panels. Hims & Hers prints Q1 May 11 the same evening.
CordenPharma's Boulder, Colorado expansion is now confirmed at $500 million, with the first phase coming online in 2026 and full completion in 2028. The site will add new large-scale manufacturing lines and a greenfield facility that more than doubles its solid-phase peptide synthesis (SPPS) capacity to over 42,000 liters by 2028 — positioning Boulder among the largest peptide production sites worldwide. CordenPharma Colorado leased 64,000 square feet at BioMed Realty's Flatiron Park 5505 Central — Boulder's first purpose-built speculative lab building — and will add more than 200 employees to the existing 700-person workforce. The expansion sits within CordenPharma's broader €900M+ ($1B+) global peptide platform investment that also includes a >€500M greenfield site near Basel.
TIDES USA 2026 — the year's leading oligo, peptide, and mRNA therapeutics conference — opens May 11–14 in Boston, with six concurrent scientific tracks and 200+ presentations. Programmatic highlights include CMC strategy for complex dual and triple agonists under regulatory scrutiny, defining defensible starting materials for GLP-1 APIs, and how CDMOs are securing scarce GMP suite capacity dominated by big-pharma volume contracts. Bachem, PolyPeptide, CordenPharma, Gilead, and Novo Nordisk teams are scheduled to speak — the same week as Hims & Hers' Q1 print and within the new AJMC oral-peptides public-facing news cycle.
ResearchAndMarkets released a Peptide and Oligonucleotide CDMO Market Research Report on April 30 forecasting the global market expanding from $2.42B in 2025 to $2.7B in 2026 (11.9% CAGR), reaching $4.03B by 2030. The report names Bachem, PolyPeptide, CordenPharma, and AmbioPharm as the dominant capacity holders capturing roughly 55–60% of global revenue. Demand for GLP-1 receptor agonists and siRNA drugs is outpacing GMP suite availability, giving CDMOs unusual pricing power in multi-year capacity contracts. The report frames manufacturing capacity as the binding constraint on the next wave of peptide therapeutics.